# PHASE I -TOPIC 431 - DRUG DELIVERY BY ENDOESOPHAGEAL LAVAGE (EEL) TO TREAT ESOPHAGEAL CANCER

> **NIH NIH N43** · ISOLA THERAPEUTICS INC · 2022 · $400,000

## Abstract

Cancer is the second leading cause of death in the United States and esophageal cancer has the 6th lowest survival rate for all cancers. Systemic drug therapy is first-line therapy for widely metastatic esophageal cancer, but is limited by systemic toxicity, patient eligibility, or cost. The proprietary Isola system consists of a drug delivery catheter, tubing, heating element, and a drug lavage solution. A proof-of concept animal study demonstrated that Isola can deliver drug directly to esophageal tissue while minimizing drug in plasma by using balloons to isolate the esophagus from the gastrointestinal track when a drug solution is delivered in the lumen of the esophagus.  The goal of is to treat cancerous tumors (adenocarcinoma and squamous cell carcinoma) in the esophagus while minimizing systemic drug exposure and toxicity.  The objective of this proposal is to advance activities to eventually complete a first in human (FIH) study using the Isola drug delivery system by a) finalizing the drug delivery system design and selecting the ideal drug for delivery b) completing device design verification and biocompatibility testing to use drug delivery system in humans and c) conducting comparative chronic animal studies to compare Isola drug delivery to standard intravenous drug delivery.

## Key facts

- **NIH application ID:** 10693518
- **Project number:** 75N91022C00018-0-9999-1
- **Recipient organization:** ISOLA THERAPEUTICS INC
- **Principal Investigator:** CRAIG BRIAN
- **Activity code:** N43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $400,000
- **Award type:** —
- **Project period:** 2022-09-15 → 2023-09-14

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10693518

## Citation

> US National Institutes of Health, RePORTER application 10693518, PHASE I -TOPIC 431 - DRUG DELIVERY BY ENDOESOPHAGEAL LAVAGE (EEL) TO TREAT ESOPHAGEAL CANCER (75N91022C00018-0-9999-1). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10693518. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*